Edwards PASCAL Precision Transcatheter Valve Repair System Receives FDA Approval For Degenerative Mitral Regurgitation

Sep 15, 2022 | Industry Press Releases

IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), today announced the company’s PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral regurgitation (DMR).